The validation of low-dose CT scans from the [18F]-FDG PET-CT scan to assess skeletal muscle mass in comparison with diagnostic neck CT scans
Authors:
Open Access
- 13 February 2023
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 50 (6) , 1735-1742
Abstract
Purpose: Radiologically defined sarcopenia, or a low skeletal muscle index (SMI), is an emerging biomarker for adverse clinical outcomes in head and neck cancer (HNC) patients. Recently, SMI measurements have been validated at the level of the third cervical vertebra (C3) on diagnostic neck CT scans but are not yet validated on low-dose (LD) neck CT scans from the [18F]-FDG PET-CT. This hampers SMI analysis in HNC patients without a diagnostic neck CT but with a [18F]-FDG PET-CT scan. Therefore, the aim was to study whether (low) SMI based on LD CT scan from [18F]-FDG PET-CT is comparable to those derived from diagnostic neck CT scans. Methods: HNC patients with both diagnostic CT and [18F]-FDG PET-CT of the neck were prospectively included into the OncoLifeS data-biobank. Skeletal muscle was retrospectively delineated at the level of the third cervical vertebra (C3), and (low) SMI (cm2/m2) was calculated for diagnostic and LD neck CTs. (Low) SMI from the diagnostic neck CT was considered the reference standard. Intra-class correlation coefficient (ICC), Bland–Altman plots, and Cohen’s Kappa analysis were performed. Results: The cohort (n = 233) mean age was 66.2 ± 12.8 years, and 74.2% of patients were male. Inter-rater reliability was excellent (ICC > 0.990, 95% confidence interval 0.975–0.996, p < 0.001). The agreement of SMI between both modalities was high according to the Bland–Altman plot (mean ΔSMI = − 0.19 cm2/m2), and there was no substantial bias. Cohen’s Kappa analysis showed an almost perfect agreement of low SMI between the two modalities (κ = 0.911, p < 0.001). The position of arms didn't affect the high agreement of (low) SMI. Conclusion: Skeletal muscle mass, as measured with (low) SMI, remains constant irrespective of CT acquisition parameters (diagnostic neck CT scans versus LD neck scans of the [18F]-FDG PET-CT scan), positioning of arms, and observers. These findings contribute to the construction of a clinically useful radiological biomarker for SMI and therefore identify patients at risk for adverse clinical outcomes.Keywords
This publication has 20 references indexed in Scilit:
- The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient’s perspectiveJournal of Translational Medicine, 2019
- CT‐measured skeletal muscle mass used to assess frailty in patients with head and neck cancerJournal of Cachexia, Sarcopenia and Muscle, 2019
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational Journal of Cancer, 2018
- Contrast-enhancement influences skeletal muscle density, but not skeletal muscle mass, measurements on computed tomographyClinical Nutrition, 2018
- Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patientsOral Oncology, 2016
- Epidemiologic Trends in Head and Neck Cancer and Aids in DiagnosisOral and Maxillofacial Surgery Clinics of North America, 2014
- Cancer cachexia update in head and neck cancer: Definitions and diagnostic featuresHead & Neck, 2014
- A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine careApplied Physiology, Nutrition, and Metabolism, 2008
- Head and neck cancerThe Lancet, 2008
- Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomographyJournal of Applied Physiology, 1998